

AREXVY Billing and Coding: Quick Reference Guide

The Following Includes Vaccine Product Codes and Some Common Administration Codes Associated With Immunization Using AREXVY

Vaccine administration codes are dependent on the services provided. Please refer to the latest edition of the Current Procedural Terminology (CPT) for appropriate administration codes, and the latest edition of International Classification of Diseases (ICD) manual for appropriate diagnosis codes.

Coding for AREXVY	
CPT Code (Product) ¹	90679
CPT Code (Administration) ²	90471: 1 vaccine administered 90472: Each additional vaccine administered during same encounter
ICD-10-CM Code ^{3*}	Z23: Encounter for immunization
MVX Code ⁴	SKB
CVX Code ⁵	303

NDCs ⁶		WAC
Outer Carton (Supplied as package of 10 doses)	10-Digit: 58160-848-11 11-Digit: 58160-0848-11 [†]	\$294 per dose

WAC—wholesale acquisition cost—is the listed price to wholesalers and warehousing chains, not including prompt-pay, stocking, or distribution allowances, or other discounts, rebates, or chargebacks. Listed prices may not represent prices charged to other customers, including specialty distributors. WAC as of November 2024.

*ICD-10-CM code Z23, Encounter for Immunization, is reported for all vaccines given within an encounter; additional ICD-10-CM coding may be needed.³

† Note that some payers require an 11-digit NDC, which involves adding a “0” immediately after the first hyphen in each GSK NDC.⁷

Indication

AREXVY is a vaccine indicated for active immunization for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in:

- individuals 60 years of age and older;
- individuals 50 through 59 years of age who are at increased risk for LRTD caused by RSV.

Important Safety Information

- AREXVY is contraindicated in anyone with a history of a severe allergic reaction (eg, anaphylaxis) to any component of AREXVY

Please see additional Important Safety Information on next page and [click here](#) for full Prescribing Information for AREXVY.

How Supplied

AREXVY is supplied as 2 components: A single-dose vial of lyophilized antigen component (powder) and a single-dose vial of adjuvant suspension component (liquid) (packaged without syringes or needles)⁶

Dosage

A single dose after reconstitution is 0.5 mL⁶

AREXVY has 3 different lot and NDC numbers corresponding to the carton, the lyophilized antigen component, and the adjuvant suspension component. When recording the lot or NDC number for a vaccine, CDC guidance states that providers may capture the lot or NDC number on either the unit of sale OR the lyophilized component of vaccines which require reconstitution such as AREXVY, depending on their established clinical workflow. For billing purposes, GSK recommends using the outer carton NDC number. For payers who require NDCs in an 11-digit format, please use: 58160-0848-11. Use of either will not impact recall processes.

Important Safety Information (cont'd)

- The results of a postmarketing observational study suggest an increased risk of Guillain-Barré syndrome during the 42 days following vaccination with AREXVY
- Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration of AREXVY
- Syncope (fainting) may occur in association with administration of injectable vaccines, including AREXVY. Procedures should be in place to avoid injury from fainting
- Immunocompromised persons, including those receiving immunosuppressive therapy, may have a diminished immune response to AREXVY
- In adults 60 years of age and older, the most commonly reported adverse reactions ($\geq 10\%$) were injection site pain (60.9%), fatigue (33.6%), myalgia (28.9%), headache (27.2%), and arthralgia (18.1%)
- In adults 50 through 59 years of age, the most commonly reported adverse reactions ($\geq 10\%$) were injection site pain (75.8%), fatigue (39.8%), myalgia (35.6%), headache (31.7%), arthralgia (23.4%), erythema (13.2%), and swelling (10.4%)
- There are no data on the use of AREXVY in pregnant or breastfeeding individuals. AREXVY is not approved for use in persons <50 years of age
- Vaccination with AREXVY may not result in protection of all vaccine recipients

References: 1. American Medical Association. CPT overview and code approval. Accessed May 21, 2024. <https://www.ama-assn.org/practice-management/cpt/cpt-overview-and-code-approval> 2. American Medical Association. CPT category I new vaccine codes (including incorporation of ACIP abbreviations listings) long descriptors. Accessed May 21, 2024. <https://www.ama-assn.org/system/files/vaccine-long-descriptors.pdf> 3. Centers for Medicare and Medicaid Services. 2023 ICD-10-CM official guidelines for coding and reporting. Accessed May 21, 2024. <https://www.cms.gov/files/document/fy-2023-icd-10-cm-coding-guidelines-updated-01/11/2023.pdf> 4. Centers for Disease Control and Prevention. Immunization information systems (IIS): HL7 standard code set, MVX – manufacturers of vaccines. May 21, 2024. <https://www2a.cdc.gov/vaccines/IIS/IISStandards/vaccines.asp?rpt=mvx> 5. Centers for Disease Control and Prevention. Immunization information systems (IIS): Current HL7 standard code set, CVX – vaccines administered. Accessed May 21, 2024. <https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx> 6. Prescribing Information for AREXVY. 7. Humana Military. Office injectable guidelines, national drug code (NDC) pricing and filing tips. Accessed May 21, 2024. <https://www.humanamilitary.com/provider/education-and-resources/claims/office-injectable>

Please see additional Important Safety Information on previous page and [click here](#) for full Prescribing Information for AREXVY.

Trademarks are owned by or licensed to the GSK group of companies.

©2025 GSK or licensor.
PMUS-RSALBND240044 January 2025
Produced in USA.